Sign in
Taking people in United StatesNo phase

Tests a flow modulation device for wide-necked brain aneurysms

Tests a flow modulation device to treat wide-necked brain aneurysms in adults.

Key facts

Who runs it
phenox Inc.
Where
Atlanta, Aurora, Boston, Buffalo, Chicago, Dallas, Englewood, Greenville, Iowa City, Jacksonville, Los Angeles, Manhasset, Nashville, New York, Oklahoma City, Park Ridge, Philadelphia, Phoenix, Portland, Salt Lake City, San Francisco, Seattle, St Louis, and Stony Brook, United StatesSee the 25 sites
Trial code
Registry title
The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms
Status
Recruiting
People taking part
214 people, planned
Started
16 Mar 2026
Expected to end
Jul 2032
Type of study
Interventional
Treatments tested
  • Flow diversion
Record updated
13 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a wide-necked brain aneurysm that has not ruptured, or has come back, to be treated with a flow modulation device (p48 MW HPC or p64 MW HPC).

Age
18 years or older
Sex
All sexes can join.
Disease stage
Unruptured or recanalized (reopened) aneurysm in the internal carotid artery or its branches; saccular or fusiform shape; neck 4 mm or wider, or dome-to-neck ratio below 2; vessel diameter 2.0 mm to 5.0 mm on both sides of the aneurysm. A previous rupture must be more than 30 days before the procedure. mRS of 2 or less before the procedure.
Earlier treatment
No earlier flow diverter or stent in the vessel carrying the aneurysm.

Main reasons for not taking part

  • Bleeding in the space around the brain (subarachnoid hemorrhage) in the past 30 days
  • True bifurcation aneurysm (at a point where the vessel splits)
  • Allergy to anticoagulants, antiplatelets, nickel, titanium or contrast agents that cannot be managed medically
  • Bleeding or clotting disorder, or platelet count below 100000
  • Pregnant, planning pregnancy during the study, or breastfeeding

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Subject is ≥ 18 years
  • Subject has a mRS ≤2 before the index procedure
  • Subject has an unruptured or recanalized intracranial aneurysm (IA). The subject may also have a previous ruptured aneurysm, provided rupture of this aneurysm has occurred more than 30 days from the index procedure. The IA must have the following characteristics below:; Saccular or fusiform morphology; Located in the internal carotid artery and its branches; Aneurysm neck ≥4 mm or dome-to-neck ratio <2; Parent vessel diameter ≥2.0mm and ≤5.0mm both distal and proximal to the target IA
  • Subject or subject's legally authorized representative (LAR) has provided written informed consent and has agreed to comply with study procedures

Who cannot take part

  • Previous flow diverter or stent within the parent vessel of the target aneurysm to be treated
  • Subarachnoid hemorrhage in the past 30 days prior to the index procedure
  • Anatomy unsuitable for endovascular procedure due to severe vessel tortuosity or stenosis, or stented ipsilateral carotid artery within 3 months prior to the index procedure
  • Major surgery in the last 30 days, including endovascular procedures, or is planned in the next 90 days after enrollment date
  • Known sensitivity to nickel, titanium metals or their alloys or any other investigational device components
  • Unstable neurologic deficit (i.e., any worsening of clinical condition in the last 30 days)
  • Irreversible bleeding disorder and/or signs of active bleeding at subject presentation
  • Contraindication or known allergies to anticoagulants or antiplatelets (e.g. aspirin, heparin, clopidogrel, prasugrel, or ticagrelor)
  • Has acute life-threatening illness other than the neurological disease (i.e., acute kidney or heart failure) to be treated in this trial
  • Known renal failure with a serum creatinine >2.5 mg/dl (or 220 μmol/l) not on dialysis
  • Known coagulopathy, or an admission International Normalized Ratio >3.0 without oral anticoagulation therapy, or an admission platelet count of <100000
  • Evidence of active infection at the time of treatment (e.g., fever, elevated white blood cell count)
  • Any other known IA requiring treatment within 3 months post-procedure
  • Has a true bifurcation aneurysm, defined as an aneurysm (saccular or non-saccular) located at the point of vessel bifurcation
  • Subject with a brain arteriovenous malformation (AVM) or other vascular malformation in the area of the target aneurysm
  • Known serious sensitivity to radiographic contrast agents that cannot be managed medically
  • Contraindication to CT scan, MRI, or angiography
  • Unable to complete the required study follow-ups
  • Participating in another clinical trial that could affect participation or primary outcomes of this study
  • Women currently pregnant or wish to become pregnant during the study or breast feeding

Where in United States

  • Piedmont Atlanta HospitalAtlanta, United StatesContact: Shardae ShaversTaking people
  • University of Colorado AnschutzAurora, United StatesContact: Jennifer Maitlen, RN, BSNTaking people
  • Tufts Medical CenterBoston, United StatesContact: Ashley ParoTaking people
  • UBNSBuffalo, United StatesContact: Michaela LaskowskiTaking people
  • Northwestern MedicineChicago, United StatesContact: Pouya NazariTaking people
  • UT Southwestern Medical CenterDallas, United StatesContact: Tyfe Oderinde, MSTaking people
  • Swedish Medical Research CenterEnglewood, United StatesContact: Ashley ThompsonTaking people
  • East Carolina University Health Medical CenterGreenville, United StatesContact: Miriam Wood, MPHTaking people
  • University of IowaIowa City, United StatesContact: Julia IveyTaking people
  • Baptist Health Research InstituteJacksonville, United StatesContact: Dollie Jennings, Ph.DTaking people
  • University of Southern California Health Sciences / Keck Hospital of USCLos Angeles, United StatesContact: Kelly HuTaking people
  • North Shore University Hospital - Northwell HealthManhasset, United StatesContact: Betsy Moclair, RN, MBA,CCRCTaking people
  • Vanderbilt University Medical CenterNashville, United StatesContact: Morgan MohlerTaking people
  • NewYork-Presbyterian Weill Cornell Medical CenterNew York, United StatesContact: Jackson HagenTaking people
  • NYU Langone HealthNew York, United StatesContact: Maria FabalTaking people
  • The University of OklahomaOklahoma City, United StatesContact: Sanaa HameedTaking people
  • Advocate Lutheran General HospitalPark Ridge, United StatesContact: Victor Arroyo, ArroyoTaking people
  • University of PennsylvaniaPhiladelphia, United StatesContact: Sophia BautistaTaking people
  • Barrow Neurological InstitutePhoenix, United StatesContact: Alex ReynoldsTaking people
  • Oregon Health & Science University Hospital (OHSU) / Oregon Stroke CenterPortland, United StatesContact: Emma BlackburnTaking people
  • University Of Utah HealthSalt Lake City, United StatesContact: Heather A MeyerTaking people
  • UCSF Medical CenterSan Francisco, United StatesContact: Atakan Orscelik, MDTaking people
  • University of Washington - Harborview Medical CenterSeattle, United StatesContact: Tyler IpTaking people
  • WashU MedicineSt Louis, United StatesContact: Ramie HeoTaking people
  • Stony Brook University HospitalStony Brook, United StatesContact: Marlene Baumeister, RN, BSN, CCRC, CNRNTaking people

About the trial

What the trial wants to find out

To determine safety and effectiveness of the p48 MW HPC and p64 MW HPC Flow Modulation Device in the treatment of wide-necked intracranial aneurysms.

The group in the trial

  • Intervention/TreatmentTreatment being tested

    Device: Flow diversion using the p48 MW HPC Device: Flow diversion using the p64 MW HPC

    Treatment: Flow diversion

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
p48/64 MW HPC in Aneurysm Occlusion (PIANO): Prospective, Multicenter, Single-arm Clinical Trial to Determine Safety and Effectiveness of the Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms.
Plain-language title
Tests a flow modulation device for wide-necked brain aneurysmsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
13 October 2026